Key Stats for Xenon Pharmaceuticals Stock
- Price change for Xenon Pharmaceuticals stock: -31%
- $XENE Stock Price as of Sep. 19: $40
- 52-Week High: $73
- $XENE Stock Price Target: $78
Now Live: Discover how much upside your favorite stocks could have using TIKR’s new Valuation Model (It’s free)>>>
What Happened?
Xenon Pharmaceuticals (XENE) stock is under pressure after the company paused enrollment in its Phase 3 psychiatry studies for major depressive disorder and bipolar disorder.
The company said it saw higher rates of neuropsychiatric side effects in these trials, including confusion, somnolence, ataxia, and rare cases of psychosis.
Xenon plans to adjust dosing, either through titration or lower doses, to improve patient tolerance before resuming enrollment.
The company’s X-NOVA2 trial for major depressive disorder had already enrolled 80% of its target 450 patients, and results are still expected in Q1 2027. Xenon will decide whether to resume the depression and bipolar trials after seeing those results.
Wall Street reacted quickly. Needham cut its price target on Xenon Pharmaceuticals stock to $60 from $78, while keeping a Buy rating.
The firm removed all sales projections for major depressive disorder and bipolar disorder from its model for AZK, the drug candidate at the center of these studies.
Needham’s new price target now reflects only AZK’s potential in epilepsy, not psychiatry.
The firm also flagged uncertainty over whether dosing changes can reduce these side effects while keeping the drug effective.
Other analysts have also weighed in.
Deutsche Bank downgraded Xenon Pharmaceuticals stock from Buy to Hold and slashed its price target from $90 to $46, citing safety concerns.
On the more optimistic side, H.C. Wainwright kept its Buy rating and $74 price target, noting that a pre-NDA meeting with the FDA raised no concerns about inadequate drug exposure levels.
Analyst price targets on Xenon Pharmaceuticals stock now range from a low of $46 to a high of $100, showing just how split opinions are on where this goes from here.
See analysts’ growth forecasts and price targets for Xenon Pharmaceuticals stock (It’s free) >>>
What the Market Is Telling Us About Xenon Pharmaceuticals Stock
A drop like this shows investors are worried about how much of Xenon’s future growth story depended on AZK succeeding in psychiatry, not just epilepsy.
The company still has more cash than debt, which gives it some cushion.
But InvestingPro data shows the stock was trading above its estimated fair value of $52.77 even before this news, and analysts don’t expect the company to be profitable this year.
The bigger question now is whether Xenon can fix the tolerability issues without weakening how well the drug works.
Until the X-NOVA2 results come out in early 2027, expect Xenon Pharmaceuticals stock to stay sensitive to any new safety updates or analyst commentary on the psychiatry program’s odds of success.
Estimate a company’s fair value instantly (Free with TIKR) >>>
How Much Upside Does Xenon Pharmaceuticals Stock Have From Here?
With TIKR’s new Valuation Model tool, you can estimate a stock’s potential share price in under a minute.
All it takes is three simple inputs:
- Revenue Growth
- Operating Margins
- Exit P/E Multiple
If you’re not sure what to enter, TIKR automatically fills in each input using analysts’ consensus estimates, giving you a quick, reliable starting point.
From there, TIKR calculates the potential share price and total returns under Bull, Base, and Bear scenarios so you can quickly see whether a stock looks undervalued or overvalued.
See a stock’s true value in under 60 seconds (Free with TIKR) >>>
Looking for New Opportunities?
- See what stocks billionaire investors are buying so you can follow the smart money.
- Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
- The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
